Femasys Inc. (FEMY)
USD 1.08
(-5.26%)
USD 1.08
(-5.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.07 Million USD | -11.13% |
| 2022 | 1.2 Million USD | 2.25% |
| 2021 | 1.17 Million USD | 13.66% |
| 2020 | 1.03 Million USD | 11.72% |
| 2019 | 929.06 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 221.48 Thousand USD | -18.31% |
| 2024 Q1 | 271.14 Thousand USD | 27.23% |
| 2023 Q2 | 320.51 Thousand USD | 9.02% |
| 2023 FY | 1.07 Million USD | -11.13% |
| 2023 Q4 | 213.11 Thousand USD | -12.79% |
| 2023 Q3 | 244.36 Thousand USD | -23.76% |
| 2023 Q1 | 293.98 Thousand USD | 25.5% |
| 2022 Q2 | 303.11 Thousand USD | -5.69% |
| 2022 Q1 | 321.4 Thousand USD | 26.37% |
| 2022 Q4 | 234.24 Thousand USD | -32.58% |
| 2022 FY | 1.2 Million USD | 2.25% |
| 2022 Q3 | 347.45 Thousand USD | 14.63% |
| 2021 FY | 1.17 Million USD | 13.66% |
| 2021 Q2 | 326 Thousand USD | -1.14% |
| 2021 Q4 | 254.32 Thousand USD | -5.66% |
| 2021 Q3 | 269.58 Thousand USD | -17.31% |
| 2021 Q1 | 329.77 Thousand USD | 17.37% |
| 2020 FY | 1.03 Million USD | 11.72% |
| 2020 Q1 | 260.51 Thousand USD | 0.0% |
| 2020 Q4 | 280.96 Thousand USD | -10.29% |
| 2020 Q3 | 313.2 Thousand USD | 70.93% |
| 2020 Q2 | 183.23 Thousand USD | -29.66% |
| 2019 FY | 929.06 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | 98.891% |
| AngioDynamics, Inc. | 303.91 Million USD | 99.647% |
| AtriCure, Inc. | 399.24 Million USD | 99.732% |
| Avinger, Inc. | 7.65 Million USD | 85.991% |
| Azenta, Inc. | 665.07 Million USD | 99.839% |
| BioLife Solutions, Inc. | 143.27 Million USD | 99.252% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 99.97% |
| Daxor Corporation | 1.28 Million USD | 16.286% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | 94.136% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | 99.045% |
| Hologic, Inc. | 4.03 Billion USD | 99.973% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.953% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 99.985% |
| KORU Medical Systems, Inc. | 28.51 Million USD | 96.241% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | 99.446% |
| Innovative Eyewear, Inc. | 1.15 Million USD | 6.986% |
| Innovative Eyewear, Inc. | 1.15 Million USD | 6.986% |
| Masimo Corporation | 2.04 Billion USD | 99.948% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | 98.896% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 99.915% |
| Nephros, Inc. | 14.23 Million USD | 92.471% |
| NovoCure Limited | 509.33 Million USD | 99.79% |
| NEXGEL, Inc. | 4.08 Million USD | 73.784% |
| NEXGEL, Inc. | 4.08 Million USD | 73.784% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | 63.175% |
| OraSure Technologies, Inc. | 405.47 Million USD | 99.736% |
| Pro-Dex, Inc. | 53.84 Million USD | 98.009% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | 39.78% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | 94.389% |
| QuidelOrtho Corporation | 2.99 Billion USD | 99.964% |
| Repligen Corporation | 638.76 Million USD | 99.832% |
| Sanara MedTech Inc. | 64.98 Million USD | 98.351% |
| STAAR Surgical Company | 322.41 Million USD | 99.668% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | 97.866% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 99.973% |
| Jin Medical International Ltd. | 19.82 Million USD | 94.592% |